spacer
home > epc > spring 2002 > understanding recent trends in pharmaceutical r&d
PUBLICATIONS
European Pharmaceutical Contractor

Understanding Recent Trends in Pharmaceutical R&D

Challenges for the Pharmaceutical Industry in the 21st Century

In recent years the environment in which the pharmaceutical industry operates has become ever more competitive. Companies large and small face tremendous pressures to increase output and remain innovative in the face of mega-mergers, rising health care costs, cost-containment initiatives, changing population demographics and the rapid emergence of new technologies.

This has driven many major pharmaceutical companies to continue to considerably increase their R&D expenditure in order to boost their pipelines and keep pace with their rivals in the race for scale. This is consistent with the view that to continue to satisfy shareholder expectations it is unlikely to be enough for pharmaceutical companies to continue with the status quo. However, the average cost of bringing a new active substance (NAS) to market (most recently estimated at US$600 million) (1), and the declining number of NASs launched in most recent years (2), illustrate the scale of this challenge.

The cost of US$600 million per NAS launched includes a significant contribution from the costs of all NASs that fail during the R&D process. In order to try and reduce this high attrition cost, many companies have put portfolio management systems into place. As development projects consume up to 10 times the resources required for a research project, particular emphasis has been placed on project selection and prioritisation, before entry into the development process. For individual companies, the costs per NAS will be affected by the company's characteristics, including its product profile, the type of technology it uses, and the type of activities it chooses to conduct in-house and those it chooses to outsource (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Faiz Kermani and Dr Gordon Findlay of CMR International

Dr Faiz Kermani joined CMR International as a Research Associate in October 1999 from Imperial College, London, where he was carrying out postdoctoral research in immunology. Previously, he obtained a PhD in Immunopharmacology from St. Thomas' Hospital, London, and a First Class Honours Degree in Pharmacology with Toxicology from King's College, London. Faiz has also worked as a Research Analyst for Danish health care company, Informedica a/s, writing on European and North American health care issues.

Dr Gordon Findlay joined CMR International in January 1997 from the University of Bristol Medical School, where he held a postdoctoral research fellowship. Previously, he gained a PhD in Biochemistry from the University of Kent at Canterbury, and a First Class Honours Degree in Biochemistry and Immunology from the University of Strathclyde.

His current position within CMR International is Manager of Strategy and Planning.


spacer
Dr Faiz Kermani
spacer
spacer
spacer
Dr Gordon Findlay
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement